Low-dose irradiation (LDI) has recently been shown to have various beneficial effects on human health, such as on cellular metabolic activities, DNA repair, antioxidant activity, homeostasis potency, and immune activation. Although studies on the immunogenic effects of LDI are rapidly accumulating, clinical trials for cancer treatment are considered premature owing to the lack of available preclinical results and protocols. Here, we aim to investigate anti-tumor and anti-metastatic effects of whole-body LDI in several tumor-bearing mouse models. Mice were exposed to single or fractionated whole-body LDI prior to tumor transplantation, and tumor growth and metastatic potential were determined, along with analysis of immune cell populations and expression of epithelial–mesenchymal transition (EMT) markers. Whole-body fractionated-LDI decreased tumor development and lung metastasis not only by infiltration of CD4+, CD8+ T-cells, and dendritic cells (DCs) but also by attenuating EMT. Moreover, a combination of whole-body LDI with localized high-dose radiation therapy reduced the non-irradiated abscopal tumor growth and increased infiltration of effector T cells and DCs. Therefore, whole-body LDI in combination with high-dose radiation therapy could be a potential therapeutic strategy for treating cancer.
Bibliographical noteFunding Information:
Funding: This work was funded by the Ministry of Trade, Industry & Energy, grant number 20131610101840, and by the Korea Institute of Radiological and Medical Sciences, funded by Ministry of Science and ICT, Republic of Korea, grant number 50538-2019. Acknowledgments: We would like to thank Su cheol Park and Moon-sik Choi (Division of Medical Radiation
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
- Abscopal effect
- Mesenchymal transition
- Systemic immune response